The HER2CLIMB-02 is the first phase III study to compare tucatinib combined with T-DM1 vs. T-DM1 alone in patients with unresectable HER2-positive BC who received a combination of taxanes with trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.